FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005778045> ?p ?o ?g. }

• W2005778045 endingPage "356" @default.
• W2005778045 startingPage "349" @default.
• W2005778045 abstract "It has been suggested that elements from the lanthanoid (Ln) series may be well suited for use as absorbing elements in X-ray contrast agents (CA). Because gadolinium, an element of the lanthanoid series, has been identified as being possibly associated with nephrogenic systemic fibrosis (NSF), a rare but potentially severe disease, we sought to determine if other lanthanoids might possess a similar potential.By computed tomography (CT), we compared the X-ray attenuation of all lanthanoids to that of iodine in vitro. In addition, we injected Han-Wistar rats on five consecutive days with 2.5 mmol Ln/kg bodyweight intravenously to test several Ln-DTPA-BMA complexes (praseodymium, europium, gadolinium, and holmium). Saline solution and a Ca-DTPA-BMA group served as controls. Ln concentrations in the skin and organs were determined by inductively coupled plasma mass spectrometry (ICP-MS). This method measures the total Ln content and cannot differentiate between chelated and unchelated Ln. In addition, serum cytokine levels were measured by Luminex technology. The complex stability of the Ln-DTPA-BMA complexes was also assessed in vitro.Lanthanoids showed up to 50% higher X-ray attenuation than iodine in CT. The highest X-ray attenuation was observed with holmium and erbium. Differences in the in vitro complex stability of Pr-, Eu-, Gd-, and Ho-DTPA-BMA complexes were observed. The complex stability differences were also reflected by differences in the concentrations in tissue of the lanthanoids in vivo. Injections of Ln complexes caused NSF-like skin lesions in rats and a rapid upregulation of pro-fibrotic and inflammatory serum cytokines. The Ca-DTPA-BMA complex did not to induce pro-fibrotic cytokines or skin lesions. Pr-DTPA-BMA appeared to be toxic; all Pr-DTPA-BMA treated animals died within the first four days of the experiment and were therefore excluded from further analyses.Lanthanoids are very well suited for higher X-ray tube voltages, particularly CT examinations. However, Ln-specific induction of NSF-like skin lesions and rapid elevation of pro-fibrotic serum cytokines levels were observed in rats following multiple administrations of high doses of Ln-DTPA-BMA complexes. The results of this animal study suggest that the stability of lanthanoid complexes may be an important consideration in evaluating the potential for in vivo safety. Furthermore the results suggest a potential of the entire class of lanthanoids to have the potential to trigger NSF-like skin lesions in rats rather than only some of the specific elements of this series." @default.
• W2005778045 created "2016-06-24" @default.
• W2005778045 creator A5000013392 @default.
• W2005778045 creator A5016164034 @default.
• W2005778045 creator A5020975288 @default.
• W2005778045 creator A5042929939 @default.
• W2005778045 creator A5045789339 @default.
• W2005778045 creator A5051250483 @default.
• W2005778045 creator A5063128550 @default.
• W2005778045 creator A5074900490 @default.
• W2005778045 date "2011-11-01" @default.
• W2005778045 modified "2023-10-07" @default.
• W2005778045 title "Efficacy and safety of lanthanoids as X-ray contrast agents" @default.
• W2005778045 cites W1995365986 @default.
• W2005778045 cites W1999260980 @default.
• W2005778045 cites W2007473559 @default.
• W2005778045 cites W2019842087 @default.
• W2005778045 cites W2020783600 @default.
• W2005778045 cites W2031641614 @default.
• W2005778045 cites W2040099348 @default.
• W2005778045 cites W2040970927 @default.
• W2005778045 cites W2047961324 @default.
• W2005778045 cites W2055883403 @default.
• W2005778045 cites W2057523017 @default.
• W2005778045 cites W2058552326 @default.
• W2005778045 cites W2060437861 @default.
• W2005778045 cites W2081741824 @default.
• W2005778045 cites W2101582810 @default.
• W2005778045 cites W2109768646 @default.
• W2005778045 cites W2114809471 @default.
• W2005778045 cites W2157433411 @default.
• W2005778045 cites W2158322653 @default.
• W2005778045 cites W2162266695 @default.
• W2005778045 cites W4240751818 @default.
• W2005778045 doi "https://doi.org/10.1016/j.ejrad.2009.10.023" @default.
• W2005778045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20006455" @default.
• W2005778045 hasPublicationYear "2011" @default.
• W2005778045 type Work @default.
• W2005778045 sameAs 2005778045 @default.
• W2005778045 citedByCount "22" @default.
• W2005778045 countsByYear W20057780452012 @default.
• W2005778045 countsByYear W20057780452013 @default.
• W2005778045 countsByYear W20057780452014 @default.
• W2005778045 countsByYear W20057780452015 @default.
• W2005778045 countsByYear W20057780452017 @default.
• W2005778045 countsByYear W20057780452018 @default.
• W2005778045 countsByYear W20057780452019 @default.
• W2005778045 countsByYear W20057780452020 @default.
• W2005778045 countsByYear W20057780452021 @default.
• W2005778045 countsByYear W20057780452022 @default.
• W2005778045 countsByYear W20057780452023 @default.
• W2005778045 crossrefType "journal-article" @default.
• W2005778045 hasAuthorship W2005778045A5000013392 @default.
• W2005778045 hasAuthorship W2005778045A5016164034 @default.
• W2005778045 hasAuthorship W2005778045A5020975288 @default.
• W2005778045 hasAuthorship W2005778045A5042929939 @default.
• W2005778045 hasAuthorship W2005778045A5045789339 @default.
• W2005778045 hasAuthorship W2005778045A5051250483 @default.
• W2005778045 hasAuthorship W2005778045A5063128550 @default.
• W2005778045 hasAuthorship W2005778045A5074900490 @default.
• W2005778045 hasConcept C120665830 @default.
• W2005778045 hasConcept C121332964 @default.
• W2005778045 hasConcept C126322002 @default.
• W2005778045 hasConcept C145148216 @default.
• W2005778045 hasConcept C150903083 @default.
• W2005778045 hasConcept C162356407 @default.
• W2005778045 hasConcept C165697059 @default.
• W2005778045 hasConcept C177322064 @default.
• W2005778045 hasConcept C178790620 @default.
• W2005778045 hasConcept C185592680 @default.
• W2005778045 hasConcept C201770740 @default.
• W2005778045 hasConcept C207001950 @default.
• W2005778045 hasConcept C2778653478 @default.
• W2005778045 hasConcept C2781027423 @default.
• W2005778045 hasConcept C2989005 @default.
• W2005778045 hasConcept C43617362 @default.
• W2005778045 hasConcept C520434653 @default.
• W2005778045 hasConcept C540056406 @default.
• W2005778045 hasConcept C557651011 @default.
• W2005778045 hasConcept C71924100 @default.
• W2005778045 hasConcept C86803240 @default.
• W2005778045 hasConceptScore W2005778045C120665830 @default.
• W2005778045 hasConceptScore W2005778045C121332964 @default.
• W2005778045 hasConceptScore W2005778045C126322002 @default.
• W2005778045 hasConceptScore W2005778045C145148216 @default.
• W2005778045 hasConceptScore W2005778045C150903083 @default.
• W2005778045 hasConceptScore W2005778045C162356407 @default.
• W2005778045 hasConceptScore W2005778045C165697059 @default.
• W2005778045 hasConceptScore W2005778045C177322064 @default.
• W2005778045 hasConceptScore W2005778045C178790620 @default.
• W2005778045 hasConceptScore W2005778045C185592680 @default.
• W2005778045 hasConceptScore W2005778045C201770740 @default.
• W2005778045 hasConceptScore W2005778045C207001950 @default.
• W2005778045 hasConceptScore W2005778045C2778653478 @default.
• W2005778045 hasConceptScore W2005778045C2781027423 @default.
• W2005778045 hasConceptScore W2005778045C2989005 @default.
• W2005778045 hasConceptScore W2005778045C43617362 @default.
• W2005778045 hasConceptScore W2005778045C520434653 @default.

• next